Ignite Creation Date:
2024-05-06 @ 10:03 AM
Last Modification Date:
2024-10-26 @ 12:24 PM
Study NCT ID:
NCT03155087
Status:
COMPLETED
Last Update Posted:
2017-05-16
First Post:
2017-05-11
Brief Title:
PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy
Sponsor:
Peoples Hospital of Zhengzhou University
Organization:
Peoples Hospital of Zhengzhou University
Study Overview
Official Title:
The Influence of AMPK Subunit Alpha PRKAA2 Genetic Polymorphisms With Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status:
COMPLETED
Status Verified Date:
2017-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Metformin is a classical oral antidiabetic drug often recommended to be the first-choice treatment of type 2 diabetes mellitus T2DM Based on the previous research on PRKAA2 STK11 and diabetes this study aimed to investigate the distributive characteristic of PRKAA2 and STK11 polymorphisms and the potential influence of STK11polymorphisms on metformin efficacy among Chinese T2DM patients discuss the association of PRKAA2 polymorphisms between T2DM patients and healthy subjects
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None